Nat. Biotechnol. 27, 682–685 (2009); published online 7 August 2009; corrected after print 8 October 2009
In the version of this article initially published, GLP-1 was incorrectly described as “glucose-lowering peptide-1”; the correct definition is “glucagon-like peptide-1.” The article also stated incorrectly that Amylin and Lilly “filed a new drug application for this drug in July...” referring to Exenatide Once Weekly. This should be corrected to “their new drug application was accepted for review by the FDA in July....” The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0809-682c
Rights and permissions
About this article
Cite this article
May, M. Erratum: Novo awaits green light for diabetes drug. Nat Biotechnol 27, 957 (2009). https://doi.org/10.1038/nbt1009-957c
Issue Date:
DOI: https://doi.org/10.1038/nbt1009-957c
